Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire ...

W ASHINGTON—Calley Means, a confidant to Health Secretary Robert F. Kennedy Jr., is taking a permanent post in the Trump ...

Amid steep cuts to US foreign assistance, the Trump administration is touting a new plan to provide a powerful HIV-prevention ...

A Coloradan who purchased an abandoned Douglas County storage unit found that it contained 1.7 million counterfeit fentanyl ...

Rep. Carlos Gimenez (R-FL) urged President Donald Trump and Secretary of State Marco Rubio on Monday to cut back on ties with ...

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish line.

But on Monday, NPR revealed that the initiative had an enthusiastic cheerleader at an even earlier stage in its development: ...

The administration’s consideration of potential military action against Maduro comes amid heightened tensions in Latin ...

Plozasiran is an apoC-III-directed small interfering ribonucleic acid designed to reduce levels of hepatic and serum apoC-III ...

President Donald Trump has repeatedly claimed that strikes on suspected drug boats his administration began carrying out in ...

Cost concerns: A new poll reveals 47 percent of Americans are concerned they can’t afford care next year, putting fresh spotlight on costs as Congress debates enhanced Affordable Care Act subsidies.